CardioComm Announces Adoption of Quarterly Reporting Exemption Under Coordinated Blanket Order 51-933
Rhea-AI Summary
CardioComm Solutions (TSXV: EKG / OTC: EKGGF) announced it will adopt the Coordinated Blanket Order 51-933 pilot to move from quarterly to semi-annual reporting (SAR). The company will be exempt from filing interim Q1 and Q3 reports in 2026 and will continue to file audited annual statements within 120 days of year-end and six-month interim reports within 60 days of June 30.
CardioComm confirms it meets SAR eligibility, including being a venture issuer, having filed required disclosures, and reporting annual revenues below $10 million on its most recent audited statements.
Positive
- Exempt from Q1 and Q3 interim filings under Coordinated Blanket Order 51-933
- Will file audited annual statements within 120 days of December 31, 2026
- Will file six-month interim reports within 60 days of June 30, 2026
- Company confirms eligibility with annual revenue below $10 million
Negative
- Investors will receive semi-annual interim financial updates instead of quarterly reports
- Less frequent interim reporting for Q1 and Q3 may reduce periodic visibility
News Market Reaction – EKGGF
In the Jul 1 session, EKGGF gained 82.61%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Toronto, Ontario--(Newsfile Corp. - May 8, 2026) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a leader in consumer heart monitoring, remote patient monitoring, and medical electrocardiogram ("ECG") software solutions, announces that it has elected to rely on Coordinated Blanket Order 51-933 Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers and move to semi-annual financial reporting ("SAR").
Coordinated Blanket Order 51-933 allows eligible venture issuers listed on the TSX Venture Exchange (the "TSXV") to voluntarily move from a quarterly to a semi-annual financial reporting framework. The Company's fiscal year ends on December 31. Under the SAR pilot program:
- Interim Period: The Company will be exempt from filing an interim financial report and related Management's Discussion & Analysis for the first quarter (Q1) ended March 31, 2026 and the third quarter (Q3) ending September 30, 2026; and
- Ongoing Reporting: CardioComm will continue to file audited annual financial statements (due within 120 days of December 31, 2026) and six-month interim financial reports (due within 60 days of June 30, 2026).
The Company confirms it meets the SAR pilot program's eligibility criteria, which include being a venture issuer with annual revenues of less than
This news release is being filed pursuant to Coordinated Blanket Order 51-933 Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers.
About CardioComm Solutions, Inc.
CardioComm Solutions, Inc. is a healthcare technology company focused on the development of medical software, remote patient monitoring solutions, and data management platforms for the collection, analysis, and reporting of cardiac and related physiological data. The Company's technologies support patients, physicians, and healthcare organizations through clinically relevant, connected digital health solutions. CardioComm has earned the ISO 13485 and ISO 27001 certifications, is HIPAA compliant and holds medical device clearances and sales licenses from the USA (FDA) and Canada (Health Canada).
FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
investor.relations@cardiocommsolutions.com
Forward-looking statements
This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm and certain of the plans and objectives of CardioComm with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.
In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/296712